Company Overview and News
INVESTORS with sharp eyes would have noticed that Yee Lee Corp Bhd has been slowly upping its stake in associate company Spritzer Bhd. As at Aug 30, Yee Lee’s stake in the mineral water company stood at 29.21%. This was after it had purchased 654,800 shares off market and 41,700 shares on the open market.
BSMAF 5584 1818
KUALA LUMPUR: YLTC Sdn Bhd, a joint-venture (JV) company between Yee Lee Corp Bhd and Tasco Bhd, has secured a contract with Shell Malaysia Trading Sdn Bhd to provide supply chain services for Shell convenience retail outlets in Peninsula Malaysia.
KUALA LUMPUR (Sept 13): Based on corporate announcements and news flow today, stocks in focus on Friday (Sept 14) may include: Westports Holdings Bhd, Bermaz Auto Bhd, Yee Lee Corp Bhd, Tasco Bhd, SMTrack Bhd, Panpages Bhd, Axiata Group Bhd, FGV Holdings Bhd, Binasat Communications Sdn Bhd, Parkson Holdings Bhd and Dataprep Holdings Bhd.
PKSGF PTXAF 3368 5246 5584 5657 PKSGY 8338 6888 PTXKY AXXTF BSMAF 1818
KUALA LUMPUR, Sept 13 —YLTC Sdn Bhd has been appointed as Shell Malaysia Trading Sdn Bhd’s contractor to provide supply chain services for Shell convenience retail outlets throughout Peninsular Malaysia beginning Oct 1, 2018.
BSMAF 5584 1818
KUALA LUMPUR (Sept 13): YLTC Sdn Bhd, a joint-venture (JV) company between Yee Lee Corp Bhd and Tasco Bhd, has secured a contract with Shell Malaysia Trading Sdn Bhd to provide supply chain services for Shell convenience retail outlets in Peninsular Malaysia.
Tasco Bhd (Aug 17, RM1.70) Maintain buy with a lower target price of RM1.96: Tasco Bhd reported a net profit of RM5.2 million for its first quarter of financial year 2019 (1QFY19) ended June 30, 2018, which inched up 1.3% quarter-on-quarter (q-o-q) but slid 27.3% year-on-year (y-o-y) with revenue growth of 7.2% q-o-q and 15.7% y-o-y. The better q-o-q performance was due to the better result by the International Business Solutions (IBS) and lower corporate costs that offset lacklustre earnings from the Domestic Business Solutions (DBS).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...